OXiGENE Inc  

(Public, NASDAQ:OXGN)   Watch this stock  
Find more results for OXGN
1.39
-0.02 (-1.42%)
Real-time:   3:34PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.38 - 1.44
52 week 1.31 - 2.83
Open 1.41
Vol / Avg. 354,676.00/463,822.00
Mkt cap 36.90M
P/E     -
Div/yield     -
EPS -0.65
Shares 26.54M
Beta 2.11
Inst. own 17%
Apr 30, 2015
Q1 2015 OXiGENE Inc Earnings Call - Webcast
Apr 30, 2015
Q1 2015 OXiGENE Inc Earnings Release
Mar 17, 2015
Full Year 2014 OXiGENE Inc Earnings Call - Webcast
Mar 17, 2015
Full Year 2014 OXiGENE Inc Earnings Release
Mar 11, 2015
OXiGENE Inc at ROTH Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -33.20% -67.06%
Return on average equity -34.46% -72.17%
Employees 13 -
CDP Score - -

Address

701 Gateway Blvd Ste 210
SOUTH SAN FRANCISCO, CA 94080-7041
United States - Map
+1-650-6357000 (Phone)
+1-650-6357001 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

OXiGENE, Inc. is a clinical-stage, biopharmaceutical company developing therapeutics primarily to treat cancer. The Company primary focus is the development of product candidates referred to as vascular disrupting agents (VDAs), that selectively disable and destroy abnormal blood vessels that provide solid tumors a means of growth and survival, and also are associated with visual impairment in a number of ophthalmological diseases and conditions. The Company’s lead compound, ZYBRESTAT, indicated for the treatment of advanced ovarian cancer and for anaplastic thyroid cancer (ATC), a rare and highly aggressive cancer. The Company is pursuing development of OXi4503, a second-generation, dual-mechanism VDA, to reduce tumor blood flow but which also forms an antiproliferative metabolite. The Company believes that this dual mechanism differentiates OXi4503 from other VDAs and may result in enhanced anti-tumor activity in certain tumor types as compared with other VDA drug candidates.

Officers and directors

Frederick W. Driscoll Chairman of the Board
Age: 64
Bio & Compensation  - Reuters
William D. Schwieterman M.D. President, Chief Executive Officer, Director
Age: 57
Bio & Compensation  - Reuters
Barbara Riching Chief Financial Officer, Vice President
Age: 56
Bio & Compensation  - Reuters
David Chaplin Ph.D. Chief Scientific Officer, Director
Age: 59
Bio & Compensation  - Reuters
Tamar D. Howson Independent Director
Age: 66
Bio & Compensation  - Reuters
Gerald McMahon Ph.D. Independent Director
Age: 60
Bio & Compensation  - Reuters